C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias
ST. LOUIS, July 15, 2025--(BUSINESS WIRE)--C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announces the launch of two new highly anticipated plasma assays for Research Use Only: C2N eMTBR-tau243 and C2N %p-tau MAA.
C2N eMTBR-tau243 (endogenous Microtubule Binding Region) is a unique blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. C2N cites research that says this may provide the potential to improve the diagnostic evaluation of Alzheimer's pathology in clinical trials, supporting essential disease staging, predicting disease progression and response to treatment, and monitoring treatment efficacy.
This new plasma assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by C2N nearly two years ago and is available for Research Use Only. C2N obtained the exclusive rights for these technologies from the Bateman Lab at WashU Medicine. With funding from the GHR Foundation, the C2N team optimized and industrialized these assays using rigorous analytical methods to bring them to their current state.
The company aims to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.
C2N Increases Diagnostic Power With C2N %p-tau MAA
C2N is also launching a novel p-tau multi-analyte assay (MAA). This assay uses high-resolution mass spectrometry (LC-MS/MS) to precisely quantitate six analytes related to phosphorylated and nonphosphorylated forms of tau (%p-tau181, %p-tau205 and %p-tau217). The C2N %p-tau MAA measures multiple phosphorylated tau forms from a single sample and, therefore, enables greater efficiencies. This test is likewise available for Research Use Only.
C2N's LC-MS/MS methodologies enable a ratio of phosphorylated tau divided by non-phosphorylated tau (%p-tau) that previously has been shown to mitigate for confounding factors such as age and medical comorbidities like kidney disease. The Journal of the American Medical Association (JAMA) published a large clinical study that found C2N's PrecivityAD2™ test accuracy was not impacted in the primary care arm of the study despite having patients of older age and with higher prevalence of comorbidities.
The company believes the C2N %p-tau MAA and C2N eMTBR-tau243 assays will play a key role in biopharma clinical trials, enabling better assessment of Alzheimer's disease pathology and supporting a precision medicine approach to novel treatment strategies. The assays will cover both early-stage and late-stage tau pathology identification, providing a robust marker for disease identification, staging, and stratification.
"Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics, first as Research Use Only tools and then in the form of clinical diagnostic tests," says C2N CEO and President Dr. Joel Braunstein. "Patients and families worried about Alzheimer's disease are pressing on the entire healthcare sector for a clearer picture of Alzheimer's disease pathology. We are responding, first for researchers and then for the broader global healthcare provider community."
The Precivity™ line of blood tests currently available clinically to aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions are: PrecivityAD®, PrecivityAD2™, and Precivity-AopE™.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit www.c2n.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250715238954/en/
Contacts
COMPANY CONTACT:Joni Hendersoninfo@C2N.com
MEDIA CONTACT:Adam ShapiroAdam.Shapiro@ASPR.bz 202-427-3603
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Study Finds Special Brain Traits of 'SuperAgers.' Here's How They Avoid Dementia
A study that began in the year 2000 is finally paying off. Northwestern University's SuperAger program has been in the works for over 25 years, and a new report in the Journal of the Alzheimer's Association is detailing what the group has found. Published on August 7, the report details the scope of the study and its results so far — 25 years out since the start. 290 people signed up to be studied in that time, all over 80 years old and cognitively well. Participants are tested for a high delayed word recall ability, signifying a higher memory capacity at an older age. These seniors that show exceptional memory are labeled "SuperAgers". Of the 290 participants, 79 allowed scientists to autopsy their brains after passing away. Because of this, researchers were able to make a connection between dementia, particularly Alzheimer's, and the structure of the brain. "Neurotypical seniors ≥ 80 years of age have significant and widespread cortical thinning compared to neurotypical 50- to 60-year-olds," the report reads, "Superagers, on the other hand, showed no cortical thinning compared to the younger controls." The brain — particularly the cerebral cortex — naturally thins as a person ages, but Northwestern's report shows that may happen less quickly in some people than in others. "It appears that cortical thinning is unavoidable," the report states, "but that it is probably much slower in superagers." Further, researchers reported that superagers' brains tend to develop few or zero amyloid plaques and tau tangles, which are two tell-tale signs of Alzheimer's disease. While no specific cause has been determined, researchers believe they're a bit closer to understanding dementia. What is dementia? Dementia is a decline in memory or mental capacity, usually found in senior citizens. Alzheimer's is the most common form of dementia, affecting around 11% of those 65 and older. There are various factors that scientists believe could lead to an increased chance of developing Alzheimer's or dementia as a person ages. Some of these factors, as found in the study by Northwestern University, are structural and genetic. Others, though, may come from a person's lifestyle. Research shows that traumatic brain injuries earlier in life, high blood pressure, untreated depression, and hearing loss may help onset dementia. Low physical activity and few meaningful personal connections may also exasperate the degenerative Finds Special Brain Traits of 'SuperAgers.' Here's How They Avoid Dementia first appeared on Men's Journal on Aug 7, 2025 Solve the daily Crossword
Business Upturn
2 days ago
- Business Upturn
Lithios Beverages Drives Excitement in NYC with Successful Sampling Events and Times Square Billboard
Photo Courtesy of Lithios Beverages NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Lithios Beverages, an innovator in functional drinks inspired by the energizing potential of lithium, just wrapped up a slate of in-store sampling events across Manhattan and Brooklyn, including at Fairway Gardens Kips Bay, Brooklyn Fair, and 2131 Broadway Street. Led by Alex and Tina Genzer, Lithios Beverages stands out with its unique fusion of flavor and function. Recent samplings saw enthusiastic crowds exploring Lithios Beverages' trio of standout flavors: Berry, Electric Lime, and Orange Mango. 'The feedback has been incredible. Everyone connects with different flavors, and the positive energy at our events was contagious,' said Tina Genzer. The spontaneous excitement around the upcoming launch of Brain Fuel+ Hydration Drink Mix was undeniable, with guests eagerly reserving their spots after learning about its breakthrough formula. Crafted with a mineral-rich base and enhanced by Max Catalyst™ for faster absorption, it delivers 71+ trace minerals from ConcenTrace®, essential electrolytes, Vitamin C, and B12—all in a clean, highly bioavailable format. Science-backed functional ingredients like GeniusPure® Alpha GPC and SalidroPure® Salidrosides support immunity, focus, mental clarity, and natural energy, while helping the body adapt to stress and combat fatigue. Consumers are invited to sign up online ahead of the official launch to receive 10% off their first order. Dustin Elliott, chief brand officer at NNB Nutrition, shared: 'Lithios Beverages captures what NNB stands for—real progress in human performance. GeniusPure® is the most concentrated, clinically researched Alpha GPC, shown to improve cognitive function with just one serving. And SalidroPure™ delivers 99% pure, naturally fermented salidrosides, offering a sustainable alternative to Rhodiola without compromising potency.' The interactive environment saw customers trying creative flavor combinations and brainstorming cocktail ideas, showing buzz building up for Lithios Beverages' next product line. ' The energy was remarkable. People started blending flavors, exchanging recipes, and already envisioning new ways to enjoy our Brain Fuel+ Hydration Drink Mix,' noted co-founder Alexander Genzer. 'Clearly, New Yorkers are looking for hydration that truly supports mind and body.' Lively testimonials continue to flood the company's Instagram (@drinklithiosbeverages). Lithios Beverages also recently made its Times Square debut with stunning billboard spots. This overwhelming support has prompted Fairway Markets to request more sampling events and secure additional inventory. Industry recognition is following suit. Lithios Beverages was spotlighted in GI's recent 'Companies to Watch' report, drawing attention to the broader growth of functional drinks inspired by the dynamic properties associated with lithium. The report, which highlights the functional beverage sector through 2033, can be accessed in the Press and Media area of the Lithios Beverages website. 'We're honored by the excitement and curiosity Lithios Beverages is generating,' said Tina Genzer. 'Just as lithium powers modern technology, Lithios Beverages energizes everyday wellness. Our upcoming Brain Fuel+ Hydration will go even further to meet today's needs for clarity, resilience, and refreshment.' Lithios Beverages is continuing in-store sampling across NYC throughout July, with more events planned for September. It has also opened a round for early-stage investors. For more information, visit or follow @drinklithiosbeverages on Instagram. Contact information:Tina GenzerLithios Beverages Website: [email protected]
New York Post
2 days ago
- New York Post
Trump can rein in healthcare costs AND win medical breakthroughs — here's how
Of all the problems bedeviling the American healthcare system, the high cost of pharmaceuticals is one of those most commonly cited by patients. Polling finds that most Americans think drugs are too expensive, and they're often right — even if pricey medications beat alternatives like surgery, hospitalization or living with pain. President Donald Trump has promised to implement healthcare reforms that both increase innovation and improve affordability. Advertisement Some see these as contradictory pursuits — but when it comes to pharmaceuticals, both of the president's goals can be achieved at the same time. This week the two of us, along with a team of top health and economic experts, launched Most Favored Patients, a working group aimed at developing reforms that will lower drug prices in ways that won't hinder or delay new drug development. Before we suggest policies that could work, let's be clear about what doesn't: government-mandated price controls. Advertisement Top-down edicts that remove the profit motive from drug research and development will do more harm than good, impeding the race to identify cures for cancer, Alzheimer's, Parkinson's, epilepsy and other cruel diseases. It's a short-sighted solution, too: It ignores the reality that 93% of US prescriptions are for very cheap generics — indeed, cheaper here than abroad — that emerge after innovators earn the necessary returns on their investments. Instead, let's try some innovations that make both medical and economic sense. First, do the easy stuff first and allow patients to buy medicines from pharmaceutical companies directly. Advertisement Our recent poll of 1,000 battleground-state voters found overwhelming 86% support for this concept, which would lower drug prices by avoiding expensive retail markups imposed by insurance companies and others. Most voters also favor Trump's intention to rein in costly middlemen like the highly concentrated pharmacy benefit manager industry, which negotiates drug prices for insurance companies. We also must require foreign countries to pay their fair share for medical innovations developed in the United States — that is, nearly all of them. Trump can use his NATO negotiations as a model here: Just as he has required Europe to pony up more for the benefits of NATO security through minimum levels of military spending, he could convince trading partners to spend more of their GDP on new drugs. Advertisement Right now, more than 70% of global pharmaceutical earnings come from the United States, even though we generate less than a quarter of global GDP. We annually spend $13,000 on healthcare per capita, while the rest of the developed world spends far less than $10,000 — partly because we allow more free-market healthcare pricing than other nations do. Trump is already implementing some of these reforms in his America First trade deals, securing some $300 billion worth of foreign commitments for new domestic pharmaceutical R&D, manufacturing and workforce investments. These commitments share the burden of finding cures that will benefit all of humanity — while fueling the American research engine that justifies the investments. Next, the Food and Drug Administration must thoroughly overhaul its antique, snail's-pace drug approval process: Many potential wonder drugs developed by small biomedical firms are shelved when that process' exorbitant costs and delays drain their capital. The FDA should fast-track experimental drugs for crippling and lethal diseases, and should expedite 'Right To Try' rules to get promising drugs to the people who need them. In addition, we believe the FDA should loosen its regulations and use economic criteria, not just clinical ones, to determine whether a drug may be fast-tracked for approval: Put simply, cheaper drugs should be allowed to come to market faster. Advertisement Finally, we're confident that price transparency in drugs and all other medical services would help drive prices down and encourage more comparison-shopping by patients. We don't buy food or gas or homes without knowing their price — but that's too often the case with drugs, hospitals and medical procedures. Republicans have been missing out on the political benefits of seizing on common-sense reforms like these. Advertisement Voters consistently view the GOP as being less caring and less reliable on solving our nation's healthcare concerns. That's made them cower. They keep their mouths shut and flee from any discussion of voters' valid complaints — and often lose elections as a result. As the midterms approach, Republicans who promote innovation with our Most Favored Patient proposals will help bring down costs, ensure American biomedical innovative supremacy, and save lives. Advertisement Everyone is on board with that. Stephen Moore is a co-founder of Unleash Prosperity, where Tomas Philipson is a senior research fellow.
